# Avandamet Bioequivalence Study Brazil - Fed Administration

> **NCT01332071** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 26 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Rosiglitazone Maleate + Metformin 2 miligrams (mg) + 500 mg
- **DRUG:** Rosiglitazone Maleate + Metformin 4 miligrams (mg) + 1000 mg

## Key facts

- **NCT ID:** NCT01332071
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11-24
- **Primary completion:** 2009-12-06
- **Final completion:** 2009-12-06
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2017-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01332071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01332071, "Avandamet Bioequivalence Study Brazil - Fed Administration". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01332071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*